Analysis of Revenues
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Net Profit Margin since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Eli Lilly & Co., income statement, revenues
US$ in thousands
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiometabolic health | |||||||||||
| Oncology | |||||||||||
| Immunology | |||||||||||
| Neuroscience | |||||||||||
| Other | |||||||||||
| Revenue |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Cardiometabolic health
- The revenue from cardiometabolic health demonstrated a consistent upward trend over the analyzed periods. Starting at 11.83 billion US dollars in 2020, it increased steadily each year, reaching approximately 29.52 billion US dollars by 2024. The growth was particularly pronounced between 2022 and 2024, where revenue surged from 14.46 billion to over 29.52 billion US dollars, indicating a strong expansion in this segment.
- Oncology
- Revenue in the oncology segment showed moderate growth overall. It rose from about 5.32 billion US dollars in 2020 to 8.75 billion in 2024. There was a slight dip in 2022 compared to 2021, declining from 5.74 billion to 5.67 billion US dollars, but this was followed by a significant rebound in 2023 and 2024, suggesting recovery and potential growth momentum in this domain.
- Immunology
- The immunology segment revenues increased steadily from 2.46 billion US dollars in 2020 to about 4.39 billion in 2024. The growth rate was relatively consistent across the years, with no notable decreases, demonstrating sustained demand and expansion within this business unit.
- Neuroscience
- Neuroscience revenues exhibited volatility over the period. Beginning at 1.83 billion US dollars in 2020, the figure showed minor growth in 2021 but then decreased to 1.55 billion in 2022. The most significant fluctuation occurred in 2023, with a sharp increase to approximately 2.88 billion US dollars, followed by a notable decline to 1.47 billion in 2024. This variability might indicate market instability or fluctuations in product performance in this segment.
- Other
- Revenues categorized as "Other" experienced a downward trajectory overall, falling from 3.09 billion US dollars in 2020 to 0.90 billion in 2024. After peaking in 2021 at 4.13 billion, revenues in this category declined sharply over the subsequent years, suggesting divestitures, reduced activity, or lower demand for products within this segment.
- Total Revenue
- Total revenues showed a consistent upward movement across the five years. Starting from 24.54 billion US dollars in 2020, revenue increased to approximately 45.04 billion in 2024. The acceleration in revenue growth is notable particularly from 2022 onward, aligning with expansions in key segments such as cardiometabolic health and oncology.